STOCK MARKET BSE NSE

Russia seeks collaboration with India for manufacturing COVID-19 vaccine Sputnik V: Sources

According to government sources, the matter was discussed by the national expert group on vaccine administration for COVID-19 in its last meeting held on August 22.

Published: 25th August 2020 08:01 PM  |   Last Updated: 26th August 2020 08:52 AM   |  A+A-

vaccine against the coronavirus disease, developed by the Gamaleya Research Institute of Epidemiology and Microbiology. (Photo | AFP)

For representational purpose. (Photo | AFP)

By PTI

NEW DELHI: The Russian government has reached out to India seeking a collaboration for manufacturing its COVID-19 vaccine 'Sputnik V' and conducting its phase 3 clinical trial here, sources said.

According to government sources, the matter was discussed by the national expert group on vaccine administration for COVID-19 in its meeting held on August 22.

Sputnik V has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology along with the Russian Direct Investment Fund (RDIF).

The vaccine has not been tested in phase 3 or larger clinical trials.

There has been scepticism in some quarters about limited data related to the efficacy of the vaccine.

"The Russian government has reached out to the Indian government seeking a collaboration for manufacturing their COVID-19 vaccine, Sputnik V, and conducting its phase 3 trial here," a source in the government said.

"The Department of Biotechnology (DBT) along with the Department of Health Research has been asked to lead and look into the matter. They (Russian government officials) have shared some information and data on Sputnik V, while more data related to the safety and efficacy of the vaccine is awaited," the source said.

When asked if the Russian government has placed any formal request for the manufacture of its COVID-19 vaccine in India, Union Health Secretary Rajesh Bhushan said at a press conference, "As far as Sputnik V vaccine is concerned, both India and Russia are in communication. Some initial information has been shared while some detailed information is awaited."

According to sources, Russian Ambassador to India Nikolay Kudashev has approached the office of Principal Scientific Advisor K VijayRaghavan as well as secretaries of the departments of biotechnology and health research in this regard.

Talking about COVID-19 vaccine development in India, ICMR Director General Balram Bhargava said, at a press briefing, on Tuesday that currently two vaccine candidates, indigenously developed by Bharat Biotech in collaboration with ICMR and Zydus Cadila Ltd, have completed phase 1 of the human clinical trials and they will start phase 2 trials.

Pune-based Serum Institute of India, which has partnered with AstraZeneca for manufacturing the Oxford COVID-19 vaccine candidate, has also started the process of conducting phase 2 and 3 human clinical trials of the candidate in India.


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp